북미와 유럽의 의약품 안정 보관 서비스 시장 규모, 점유율, 동향 분석 리포트 : 서비스별, 분자별, 국가별, 부문별 예측(2025-2030년)

North America And Europe Pharmaceutical Stability & Storage Services Market Growth & Trends:

The North America and Europe pharmaceutical stability & storage services market is anticipated to reach USD 1.92 billion by 2030. It is anticipated to expand at a CAGR of 6.4% during the forecast period, according to a new report by Grand View Research, Inc. Stringent regulatory requirements, increasing R&D investments, and globalization of clinical trials are some of the major factors driving market growth.

The rising demand for biosimilars is expected to drive market advancement. In recent years, the approval rate for biosimilars has significantly improved. As per the Amgen Biosimilars Trend Report published in 2020, the number of biosimilar approvals in the U.S. increased by 65% since the preceding year. As of 2023, 41 biosimilars were approved in the U.S., and over 70 were approved in the EU. The growing approval of biosimilars is likely to impact the market positively.

In addition, the shift toward personalized medicine in these regions necessitates stability testing tailored to the distinct features of individualized treatments, ensuring that patient-specific therapies remain effective. Technological innovations have also transformed the landscape, integrating automation, advanced data analytics, and real-time monitoring technologies, streamlining stability testing processes, and accelerating decision-making. These advancements enhance operational effectiveness and provide immediate insights into product behavior, further propelling market growth.

Furthermore, the pharmaceutical industries in North America and Europe benefit from highly developed infrastructure equipped with state-of-the-art facilities for stability testing and storage, supporting the complex requirements of modern pharmaceuticals, including temperature-sensitive products. The increasing pipeline of new drugs, especially biologics and specialty medicines with unique storage needs and shorter shelf lives, also drives demand for advanced stability and storage solutions.

North America And Europe Pharmaceutical Stability & Storage Services Market Report Highlights:

• The stability testing segment dominated the service segment. It held the largest revenue share of 73.8% in 2024. The rapid growth in the demand for biopharmaceuticals and personalized medicines is driving advancements in pharmaceutical stability services
• The storage segment is expected to grow at a CAGR of 5.8% over the forecast period, owing to the increasing focus on generics and biosimilars in developing regions.
• The small molecules segment dominated the market, with the largest revenue share of 79.4% in 2024. Recent advances in forecasting, structure-based design, imaging, automation, artificial intelligence, and machine learning have become critical facilitators for increasing small molecules lead optimization's pace and success rates
• The large molecules segment is expected to grow at a significant CAGR from 2025 to 2030. This is due to the increasing adoption of large molecules such as proteins, nucleic acids, carbohydrates, living cells, and tissues.
• North America dominated the pharmaceutical stability & storage services market. It held the largest revenue share in 2024, driven by the growing pipeline of complex drugs, including biologics and personalized medicines, necessitating specialized stability testing and controlled storage solutions, fueling market expansion.
• Europe is also expected to account for a significant market share in the coming years. The UK has a strong emphasis on R&D in the pharmaceutical sector. As companies invest in developing new drugs and conducting clinical trials, there is an increased demand for stability testing and storage services to support these activities

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Molecule
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Service Outlook
  • 2.2.2. Molecule Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. North America and Europe Pharmaceutical Stability and Storage Services Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. North America and Europe Pharmaceutical Stability and Storage Services Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. North America and Europe Pharmaceutical Stability and Storage Services Market: Service Business Analysis

• 4.1. Service Segment Dashboard
• 4.2. Pharmaceutical Stability and Storage Services Market: Service Movement Analysis
• 4.3. North America and Europe Pharmaceutical Stability and Storage Services Market Size & Trend Analysis, By Service, 2018 to 2030 (USD Million)
• 4.4. Stability Testing
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Drug Substance
    • 4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Stability Indicating Method Validation
    • 4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Accelerated Stability Testing
    • 4.4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Photo Stability Testing
    • 4.4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Other Stability Testing Methods
    • 4.4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Storage
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Cold
    • 4.5.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Non-Cold
    • 4.5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. North America and Europe Pharmaceutical Stability and Storage Services Market: Molecule Business Analysis

• 5.1. Molecule Segment Dashboard
• 5.2. Pharmaceutical Stability and Storage Services Market: Molecule Movement Analysis
• 5.3. North America and Europe Pharmaceutical Stability and Storage Services Market Size & Trend Analysis, By Molecule, 2018 to 2030 (USD Million)
• 5.4. Small Molecule
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Research Products
    • 5.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Commercial Products
    • 5.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Large Molecule
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Research Products
    • 5.5.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Commercial Products
    • 5.5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. North America and Europe Pharmaceutical Stability and Storage Services Market: Country Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. North America and Europe Pharmaceutical Stability and Storage Services Market by Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key Country Dynamics
    • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.1.3. Competitive Scenario
    • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.2.3. Competitive Scenario
    • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Germany
    • 6.5.1.1. Key Country Dynamics
    • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.1.3. Competitive Scenario
    • 6.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Denmark
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.6.3. Competitive Scenario
    • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.7.3. Competitive Scenario
    • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Norway
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.8.3. Competitive Scenario
    • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key Company Heat Map Analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Eurofins Scientific
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Intertek Group plc
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Lucideon Limited
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Element Materials Technology
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Q1 Scientific
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Reading Scientific Services Ltd.
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Catalent, Inc.
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Quotient Sciences
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Recipharm AB
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Almac Group
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives
  • 7.4.11. Alcami Corporation
    • 7.4.11.1. Company Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Product Benchmarking
    • 7.4.11.4. Strategic Initiatives
  • 7.4.12. BioLife Solutions, Inc.
    • 7.4.12.1. Company Overview
    • 7.4.12.2. Financial Performance
    • 7.4.12.3. Product Benchmarking
    • 7.4.12.4. Strategic Initiatives
  • 7.4.13. Sampled (Roylance Stability Storage Limited)
    • 7.4.13.1. Company Overview
    • 7.4.13.2. Financial Performance
    • 7.4.13.3. Product Benchmarking
    • 7.4.13.4. Strategic Initiatives
  • 7.4.14. Precision Stability Storage
    • 7.4.14.1. Company Overview
    • 7.4.14.2. Financial Performance
    • 7.4.14.3. Product Benchmarking
    • 7.4.14.4. Strategic Initiatives
  • 7.4.15. Broughton
    • 7.4.15.1. Company Overview
    • 7.4.15.2. Financial Performance
    • 7.4.15.3. Product Benchmarking
    • 7.4.15.4. Strategic Initiatives